Source comparison
Using BPC-157 for Bone Health Research Evidence: Study Design Comparison
Rat tibial osteotomy (Zagreb, 2019) Complete transverse fracture 10 mcg/kg daily SC × 21 days Radiographic union at 21 days 78% union vs 41% (p<0.01) Small sample (n=24), single-center, short follow-up Rat femoral fracture (Bone, 2020) Mid-diaphyseal fracture
This comparison does not assign a generated winner or score.
- Rat tibial osteotomy (Zagreb, 2019)
- Complete transverse fracture
- 10 mcg/kg daily SC × 21 days
- Radiographic union at 21 days
- 78% union vs 41% (p<0.01)
- Small sample (n=24), single-center, short follow-up
- Rat femoral fracture (Bone, 2020)
- Mid-diaphyseal fracture
- 10 mcg/kg daily SC × 28 days
- Biomechanical load to failure
- 312N vs 221N (+41%, p<0.05)
- No long-term remodeling data, no dose-response curve
- Rabbit radial defect (Reg Peptides, 2018)
- 5mm segmental defect
- 20 mcg/kg daily SC × 42 days
- Histological bone volume fraction
- 62% vs 38% (p<0.01)
- Critical-size defect model (doesn't spontaneously heal), unclear human translatability
- Human case series (unpublished, European clinic)
- Metatarsal stress fractures (athletes)
- 250–500 mcg SC BID × 4–6 weeks
- Subjective pain reduction, return to sport
- Reported faster return vs historical controls
- No randomization, no imaging verification, recall bias, publication bias
- Bottom Line
- Animal models show consistent 20–40% acceleration in bone union timelines and improved biomechanical strength at early healing phases. But human evidence is entirely anecdotal without controlled trial design, standardized dosing, or regulatory oversight.